ReviewArchives of microbiology2023
Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents.
Review in Archives of microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Insights intoFrontiers in microbiology · 2024Pooled it
- Phytochemical-driven angiogenesis and mucosal regeneration in gastric ulcer healing: molecular mechanisms, preclinical evidence, and translational perspectives.Molecular biology reports · 2026Review
- Multifunctional activity of Mentha piperita essential oil nanoemulsion against Helicobacter pylori.Scientific reports · 2026Article
- Identification of plasmid-mediated quinolone resistance genes inIranian journal of microbiology · 2026Article
- Novel anti-virulence strategy againstFrontiers in microbiology · 2026Article
- Current concepts of Helicobacter pylori infection.European journal of medical research · 2025Review
- Multifunctional bioactivity of eco-friendly Penicillium gladioli extract against Toxoplasma gondii and Pseudomonas aeruginosa.Scientific reports · 2025Article
- In vitro anti-Helicobacter pylori activity and phenotypic screening of novel quinolone compounds.Archives of microbiology · 2025Article
- Employing diclofenac sodium as a novel therapeutic frontier for Staphylococcus epidermidis infections.Scientific reports · 2025Article
- Monoterpene Indole Alkaloids with Antimicrobial Activity AgainstInternational journal of molecular sciences · 2025Article
- Update on molecular pathogenesis ofWorld journal of gastrointestinal pathophysiology · 2025Review
- Terpene-Based Eutectic Solvent Microdroplets: A Strategy to Combat Antibiotic-ResistantLangmuir : the ACS journal of surfaces and colloids · 2025Article
- Antagonist Targeting the Species-Specific Fatty Acid Dehydrogenase/Isomerase FabX for Anti-H. pylori Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Repurposing FDA-Approved Agents to Develop a PrototypePharmaceuticals (Basel, Switzerland) · 2025Article
- Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation.BMC microbiology · 2024Article
- Arthrospira maxima and biosynthesized zinc oxide nanoparticles as antibacterials against carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii: a review article.Microbial cell factories · 2024Review
- Antibacterial and wound healing potential of biosynthesized zinc oxide nanoparticles against carbapenem-resistant Acinetobacter baumannii: an in vitro and in vivo study.Microbial cell factories · 2024Article
- Association of oxidative balance score with Helicobacter pylori infection and mortality among US population.European journal of nutrition · 2024Article
- Targeted nanotherapeutics for the treatment of Helicobacter pylori infection.Journal of biomedical science · 2024Review
- The Antibacterial Potential of Brazilian Red Propolis against the Formation and Eradication of Biofilm ofAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori is considered one of the most prevalent human pathogenic microbes globally. It is the main cause of a number of gastrointestinal ailments, including peptic and duodenal ulcers, and gastric tumors with high mortality rates. Thus, eradication of H. pylori is necessary to prevent gastric cancer. Still, the rise in antibiotic resistance is the most important challenge for eradication strategies. Better consideration of H. pylori virulence factors, pathogenesis, and resistance is required for better eradication rates and, thus, prevention of gastrointestinal malignancy. This article is aimed to show the role of virulence factors of H. pylori. Some are involved in its survival in the harsh environment of the human gastric lumen, and others are related to pathogenesis and the infection process. Furthermore, this work has highlighted the recent advancement in H. pylori treatment, as well as antibiotic resistance as a main challenge in H. pylori eradication. Also, we tried to provide an updated summary of the evolving H. pylori control strategies and the potential alternative drugs to fight this lethal resistant pathogen. Recent studies have focused on evaluating the efficacy of alternative regimens (such as sequential, hybrid, concomitant treatment, vonoprazan (VPZ)-based triple therapy, high-dose PPI-amoxicillin dual therapy, probiotics augmented triple therapy, or in combination with BQT) in the effective eradication of H. pylori. Thus, innovating new anti-H. pylori drugs and establishing H. pylori databanks are upcoming necessities in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.